gefitinib has been researched along with navitoclax in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (navitoclax) | Trials (navitoclax) | Recent Studies (post-2010) (navitoclax) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 429 | 15 | 401 |
| Protein | Taxonomy | gefitinib (IC50) | navitoclax (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.0043 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0091 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0168 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 1.0925 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Arsiwala, TA; Blethen, KE; Fladeland, R; Gao, W; Liu, Z; Lockman, PR; Marshall, KL; Mohammad, A; Saralkar, P; Shah, N; Sprowls, SA | 1 |
3 other study(ies) available for gefitinib and navitoclax
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2021 |